Extend the Life Line…

COMPOSITION

Sacubitril 24mg + Valsartan 26mg TABLETS

INDICATION

Chronic Heart Failure

SCUBATRIL-50

• The first agent approved in a new class of drugs called angiotensin receptor neprilysin inhibitor
• FDA approved to treat patients with chronic heart failure with reduced ejection fraction
• Combination performs better than Enalapril across various heart failure patients and shows substantial benefits in patients with other common comorbidities
• The PARADIGM-HF trial showed that treatment of heart failure with Valsartan/Sacubitril reduced the risk of the first occurrence of either cardiovascular death or HF-related hospitalization by 20% compared with Enalapril
• More effective for the management of hypertension patients as compared to ARB